menu
    • menu
    [{"orgOrder":0,"company":"DKSH","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and DKSH partner to bring key biosimilar to Asia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"DKSH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DKSH \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"DKSH \/ DKSH"},{"orgOrder":0,"company":"DKSH","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"DKSH","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"DKSH \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"DKSH \/ DKSH"},{"orgOrder":0,"company":"DKSH","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"DKSH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"DKSH \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"DKSH \/ DKSH"},{"orgOrder":0,"company":"DKSH","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai To Divest Rights For Muscle Relaxant Myonal\u00ae And Vertigo And Equilibrium Disturbance Treatment Merislon\u00ae In Asia To DKSH","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Eperisone Hydrochloride","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"DKSH","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DKSH \/ DKSH","highestDevelopmentStatusID":"12","companyTruncated":"DKSH \/ DKSH"},{"orgOrder":0,"company":"DKSH","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuance Pharma Announces Partnership With DKSH To Launch Bentrio\u2122 Nasal Spray In Hong Kong And Macau","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Bentonite","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DKSH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"DKSH \/ DKSH","highestDevelopmentStatusID":"12","companyTruncated":"DKSH \/ DKSH"}]

    Find Clinical Drug Pipeline Developments & Deals by DKSH

    Menu

    DKSH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DKSH

                            Switzerland arrow
                            CPhI Worldwide, Milan
                            Booth #6C42
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

                            Lead Product(s) : Bentonite,Mono Propylene Glycol,Citric Acid

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Nuance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nuance Pharma Announces Partnership With DKSH To Launch Bentrio™ Nasal Spray In Hong Kong And Macau

                            Details : Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.

                            Brand Name : Bentrio

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : Bentonite,Mono Propylene Glycol,Citric Acid

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Nuance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DKSH Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DKSH

                            Switzerland arrow
                            CPhI Worldwide, Milan
                            Booth #6C42
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

                            Lead Product(s) : Eperisone Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Eisai To Divest Rights For Muscle Relaxant Myonal® And Vertigo And Equilibrium Disturbance Treatment Merislon...

                            Details : Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.

                            Brand Name : Myonal

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 07, 2022

                            Lead Product(s) : Eperisone Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DKSH Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DKSH

                            Switzerland arrow
                            CPhI Worldwide, Milan
                            Booth #6C42
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

                            Lead Product(s) : Delgocitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Leo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Throm...

                            Details : The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regiona...

                            Brand Name : LP0133

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 29, 2022

                            Lead Product(s) : Delgocitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Leo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DKSH Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            DKSH

                            Switzerland arrow
                            CPhI Worldwide, Milan
                            Booth #6C42
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Recipient : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Ph...

                            Details : The biosimilars planned under this agreement include biosimilar of Prolia® (denosumab, AVT03), Xgeva® (denosumab), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.

                            Brand Name : AVT03

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 07, 2022

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Recipient : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DKSH Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            DKSH

                            Switzerland arrow
                            CPhI Worldwide, Milan
                            Booth #6C42
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and DKSH partner to bring key biosimilar to Asia

                            Details : Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 24, 2020

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DKSH Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth